Table 1.
The Prevalence of Chronic Respiratory Diseases in Patients With COVID-19.
| Study | Sample Size | Age (Yrs) | Prevalence [(N, %)] and Impact |
|||
|---|---|---|---|---|---|---|
| Any Chronic Respiratory Diseases | COPD | Asthma | Bronchiectasis | |||
| Guan, 2020a2 | 1590 | 48.9 | NA | 24 (1.5%)• | NA | NA |
| Posso, 20203 | 834 | 78.2 | 143 (17.1%)○ | NA | NA | NA |
| Guan 20214 | 39,420 | 55.7 | 1123 (2.8%)* | 636 (1.6%)• | 244 (0.6%)• | 313 (0.7%)○ |
| Zhang, 20207 | 140 | 57.0 | ≥2 (1.4%)○ | 2 (1.4%)○ | 0 | NA |
| Guan,2020b8 | 1099 | 47.0 | NA | 261 (1.1%)* | NA | NA |
| Bloom, 20219 | 75,463 | NA | <20,196 (26.8%)• | NA | 7859 (10.4%)• | NA |
| Aveyard, 202110 | 14,497 | 69.9 | 4140 (28.6%)• | 1555 (10.7%)• | 2266 (15.7%)• | 319 (2.2%)• |
| Signes-Costa, 202013 | 5868 | 65.1 | ≥845 (14.4%)• | 483 (8.3%)• | 362 (6.2%)• | NA |
| Yang, 202015 | 7340 | 47.1 | ≥1075 (14.6%)* | 350 (4.8%)* | 725 (9.9%)• | NA |
| Chhiba, 202019 | 1526 | NA | NA | NA | 220 (14%)• | NA |
| Garcia-Pachon, 202020 | 168 | 66.0 | ≥16 (9.5%)• | 12 (7.1%)• | 4 (2.4%)• | NA |
Shown with the cells are the absolute number and the percentage. Age is expressed as the mean or median. Chronic respiratory disease: having at any of COPD, asthma and bronchiectasis. •: negative impact on the outcome of COVID-19; ○: no adverse impact on the outcome of COVID-19. *: unknown impact on the outcome of COVID-19; NA: not available.